Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Rhea-AI Summary
Ovid Therapeutics (NASDAQ: OVID), a biopharmaceutical company focused on developing medicines for brain conditions, has announced its participation in the TD Cowen 45th Annual Health Care Conference. Meg Alexander, President and Chief Operating Officer, will deliver a presentation on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.
Investors and interested parties can access the live webcast through the Events & Presentations section at investors.ovidrx.com. A replay will remain available on the company's website for approximately 30 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – OVID
In the trading session that priced this news, OVID declined 1.19%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachusetts.
A live webcast of the TD Cowen presentation can be accessed through the Events & Presentations section of the company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation for approximately 30 days.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that have the potential to modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, and a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders; and OV888/GV101, a highly selective ROCK2 inhibitor, for undisclosed neurovascular and neuro-inflammatory conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.
Investor Relations:
Garret Bonney
617-735-6093
gbonney@ovidrx.com
